Peripheral artery disease (PAD) is a common atherosclerotic syndrome that affects an estimated 8.5 million Americans and more than 200 million people worldwide. 1 Unfortunately, PAD often goes undiagnosed. Based on national treatment patterns, likely more than half of all patients with PAD do not know they have it. 2 Left undetected and untreated, PAD significantly increases the risk for myocardial infarction (MI) and stroke, and can lead to gangrene and amputation. 3, 4 Despite a cardiovascular risk that meets or exceeds coronary artery and cerebrovascular disease, neither diagnostic nor screening modalities are covered medical services for most patients. How did this come about?
The ankle-brachial index (ABI) is the standard first PAD diagnostic test. Prior to the current understanding that atherosclerosis is a systemic disease, the primary use of the ABI was in the setting of intermittent claudication or critical limb ischemia. A low ABI suggests a vascular cause for limb pain with ambulation and provides prognostic information for acral ulcer healing. In both 1996 and 2005, the United States Preventive Services Task Force (USPSTF) evaluated the value of ABI screening in asymptomatic patients for the prevention of 'PAD-specific morbidity', 5 finding that screening this population did not reduce 'PADspecific morbidity' and may cause harm. We argued in 2006 that cardiovascular disease (CVD) was the most important endpoint for PAD patients without limb symptoms; 6 however, the USPSTF responded that their charge was only to 'improve the health outcomes for PAD', 7 suggesting by implication that heart attack, stroke, and death are not PAD health outcomes.
Despite protestations, this approach was replaced in the next review in 2013 when the USPSTF 'reviewed the evidence on the use of resting ankle-brachial index (ABI) as a screening test for PAD or as a risk predictor for cardiovascular disease (CVD)'. 8 However, the definition of the patient population, patients with asymptomatic limbs, remained the same. Thus, CVD risk screening became dependent on leg muscle symptoms -an illogical disconnect that remains unexplained even today. Worse, this continues to be the approach of the Task Force in the current assessment process.
PAD markedly increases the risk of CVD with and without limb symptoms. 9 Despite strong evidence that the ABI, when added to the Framingham Risk Score, reclassifies the risk category of 19% of men and 36% of women, 10 ABI screening received an (I)nsufficient information recommendation from the USPSTF. The influence of the USPSTF should not be underestimated; the Centers for Medicare and Medicaid Services (CMS) does not cover a diagnostic ABI for patients without limb symptoms -even with abnormal physical examination findings, such as lower extremity pulse deficits. In contrast, asymptomatic patients with physical examination signs of abdominal aortic aneurysm and carotid artery disease do have a covered diagnostic ultrasound test.
As a result of this multi-decade stance by the USPSTF and CMS, the primary care community neither solicits limb complaints, routinely performs the lower extremity pulse examination, nor obtains ABI testing, despite a risk profile similar to or greater than prior MI and stroke. Indeed, both the American College of Physicians and the American Association of Family Practice refer to the USPSTF statement for ABI practice recommendations, and routine pulse examination is not part of the standard adult well male examination. 11, 12 I believe this approach is no longer tenable. There are currently four and soon to be six Food and Drug Administration-approved medications specifically for PAD that reduce cardiovascular events (clopidogrel, simvastatin, ramipril, and vorapaxar). Not just symptomatic PAD -all PAD. There are millions of patients who may benefit but are being denied current well-accepted, guideline-directed medical care. This has become even more pressing, as the most recent medications approved (or soon to be) for patients with PAD, including vorapaxar, 3 rivaroxaban, 13 and evolocumab, 4 not only reduce cardiovascular events but also reduce adverse limb events.
In this issue of Vascular Medicine, Itoga and colleagues evaluated the cost effectiveness of initiating medical therapy (statin and angiotensin-converting enzyme inhibitor) after a positive screen for PAD in 65-year-old patients. 14 They reported an incremental cost of $338 and 0.00380 quality-adjusted life years (QALY) for a $88,758/QALY over a 35-year period. In higher risk groups, like smokers where the prevalence may be higher, the incremental costeffectiveness ratio decreases significantly to $24,092/
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Cardiovascular Division, Vanderbilt University Medical Center, Nashville, TN, USA QALY. Based on the analysis, I agree with the conclusion of the authors: 'The lack of high-quality data leads to an indeterminate conclusion on whether PAD screening with the ABI test is truly below the generally accepted thresholds for cost effectiveness'. Despite the high cost of screening using these assumptions for the model, I think the lack of data has skewed the costs to be significantly higher in the article than in real life. This is not supposition, for a definitive study has been recently completed and reported. 15 The Viborg Vascular (VIVA) trial included all men aged 65-74 years living in Central Denmark. 15 The area represents 23% of the entire Danish population. The investigators randomly allocated 50,156 men to the vascular screening invitation or non-screening group. Vascular screening included ultrasound for abdominal aortic aneurysm (AAA), ABI, and blood pressure measurement. Of the men invited for screening, 18,748 attended. Over the course of 4.4 years of follow up, there was a statistically significant 7% reduction in mortality in the screening group compared to the usual care group for a number needed to invite of 169 to save one life (compared to 1339 for mammography for women aged 50-59 years and 282 for colorectal screening). Moreover, in the data supplement, the authors report only 67 deaths from AAA, non-significantly split between groups. 15 The greatest reduction in death was from cardiovascular disease, whereas there was no difference in cancer-related or other cause-related mortality. Finally, subjects in the screening arm were admitted 9% less and spent 19% less time in the hospital for PAD-related events. Thus, vascular screening decreased death, increased medication usage, and decreased time in hospital for PADrelated disease.
The article by Itoga and colleagues and the VIVA trial both make clear that PAD screening is a reasonable medical intervention with an acceptable cost in a CMS patient population. It is this author's opinion that, based on these data, the USPSTF should now give ABI screening in the Medicare population an 'A' rating and invested cardiovascular professional organizations should update the screening recommendation in the multi-specialty PAD guidelines to Class I for people greater than 65 years of age. 16 
